| Data variable | Description: | Coding: | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | Age at initial diagnosis | Integer or blank | |||||||||||||||||||||||||||||||||||
| Year | Year of initial diagnosis | Integer or blank | |||||||||||||||||||||||||||||||||||
| Primary Histology | Most prominent Histologic type | 01 = Ductal (NOS) 08 = Lobular |
|||||||||||||||||||||||||||||||||||
| Secondary Histology | Secondary Histologic type (if any) | 00 = None 01 = Ductal (NOS) 02 = Tubular 03 = Papillary 04 = Mucinous 05 = Medullary 06 = Cribiform 07 = Adenoid Cystic 08 = Lobular 09 = Mixed Lobular/Ductal 88 = Other, specify |
|||||||||||||||||||||||||||||||||||
| Laterality of primary breast cancer | Origin of the primary breast cancer | 1 = Right 2 = Left 9 = Unknown |
|||||||||||||||||||||||||||||||||||
| T Stage | AJCC (version 5) T stage | Stage I/II/III Prognostic TMAs: T1 = Tumor < 20 mm T1a = Tumor < 5 mm T1b = Tumor > 5 mm and <10 mm T1c = Tumor > 10 mm and < 20 mm Stage II/III Prognostic TMAs only: T2 = Tumor > 20 mm and < 50 mm T3 = Tumor > 50 mm Stage III Prognostic TMA only: T4 = Tumor any size + extension T4a = Extension to chest wall T4b = Edema or ulceration or satellite skin nodules T4c = Both T4a and T4b T4d = Inflammatory carcinoma |
|||||||||||||||||||||||||||||||||||
| N Stage | AJCC (version 5) N stage | Stage I/II/III Prognostic TMAs: N0 = No evidence of regional LN involvement Stage II/III Prognostic TMAs only: N1 = Mets to movable, ipsilateral node N1a = Only micromets (< 2 mm) N1b = Any nodal mets > 2 mm N1b1 = Mets to 1-3 nodes, any > 2 mm and all <20 mm N1b2 = Mets to 4 or more nodes, any > 2 mm and all < 20 mm N1b3 = Extension of tumor beyond node capsule, < 20 mm N1b4 = Mets to nodes > 20 mm Stage III Prognostic TMA only: N2 = Mets to ipsilateral nodes that are fixed to one another or to other structures N3 = Mets to ipsilateral internal mammary lymph node NX = Minimum requirement not met (unknown) |
|||||||||||||||||||||||||||||||||||
| M Stage | AJCC (version 5) M stage | M0 = No known distant metastases | |||||||||||||||||||||||||||||||||||
| Tumor Size | Measurement (in cm) of the longest diameter of the tumor | Integer or blank | |||||||||||||||||||||||||||||||||||
| Number of Nodes Positive | Number of nodes positive at initial diagnosis | 00 = All nodes negative 01-96 = Number of nodes positive 97 = 97 or more nodes positive 98 = Positive nodes, number unspecified 99 = Unknown if nodes positive or negative |
|||||||||||||||||||||||||||||||||||
| Number of Nodes Examined | Number of nodes examined at initial diagnosis | 00 = No nodes examined 01-96 = Number of nodes examined 97 = 97 or more nodes examined 98 = Nodes examined, number unspecified 99 = Unknown if nodes examined |
|||||||||||||||||||||||||||||||||||
| Type of Surgery | Type of the most comprehensive procedure performed as part of the initially planned surgery | 00 = Biopsy, NOS 10 = Partial Mastectomy WITHOUT Axillary Lymph Node Dissection 20 = Partial Mastectomy WITH Axillary Lymph Node Dissection 30 = SubQ Mastectomy WITH OR WITHOUT Axillary Lymph Node Dissection 40 = Mastectomy WITHOUT Axillary LymphNode Dissection 50 = Mastectomy WITH Axillary LymphNode Dissection 60 = Radical Mastectomy WITH Dissection of Majority of Pectoralis Major WITH Axillary LymphNode Dissection 90 = Mastectomy, NOS |
|||||||||||||||||||||||||||||||||||
| Tubule Formation | Percentage of tubular structures | 1 = > 75 % 2 = > 10 to > 75 % 3 = < 10% |
|||||||||||||||||||||||||||||||||||
| Nuclear Pleomorphism | Qualitative and quantitative evaluations of the nuclei | 1 = When the tumor cell nuclei are small with regular outlines, vary little in size and have uniform nuclear chromatin 2 = When the tumor cell nuclei are larger than normal, have open vesicular nuclei with visible nucleoli and have a moderate variability in size and shape 3 = When nuclei show marked variation is size and shape, especially when there are bizarre shapes, and/or prominent enlarged or multiple nucleoli |
|||||||||||||||||||||||||||||||||||
| Mitotic Counts | Mitotic counts are to be performed at the periphery of the tumor. Ten high power fields are counted. |
|
|||||||||||||||||||||||||||||||||||
| Tumor Grade | Total score calculated from the extent of tubule formation, nuclear pleomorphism, and mitotic count. | 1 = Grade I 2 = Grade II 3 = Grade III |
|||||||||||||||||||||||||||||||||||
| Chemotherapy | Performed as part of initial, planned anti-cancer therapy. | 0 = No 1 = Yes |
|||||||||||||||||||||||||||||||||||
| Radiation therapy | Performed as part of initial, planned anti-cancer therapy. | 0 = No 1 = Yes |
|||||||||||||||||||||||||||||||||||
| Hormone therapy | Performed as part of initial, planned anti-cancer therapy. | 0 = No 1 = Yes |
|||||||||||||||||||||||||||||||||||
| Immunotherapy | Performed as part of initial, planned anti-cancer therapy. | 0 = No 1 = Yes |
|||||||||||||||||||||||||||||||||||
| Other Therapy | Performed as part of initial, planned anti-cancer therapy. | 0 = No 1 = Yes |
|||||||||||||||||||||||||||||||||||
| Vital Status | Vital status at last contact | 1 = Alive 2 = Dead |
|||||||||||||||||||||||||||||||||||
| Length of follow-up for overall survival (OS) | Number of months from date of diagnosis to date of death due to any cause, or to date last known alive. | Integer or blank | |||||||||||||||||||||||||||||||||||
| Cancer status at death (if deceased) | Any evidence of the breast cancer at the time of death. | 0 = No evidence of breast cancer 1 = Evidence of this primary breast cancer (includes never disease-free, recurrent or metastatic cancer from primary). 2 = Another cancer is present, or the cancer present is of undetermined origin. 9 = Unknown |
|||||||||||||||||||||||||||||||||||
| Type/site of first recurrence (if any) outside of ipsilateral breast | The first recurrence outside of the ipsilateral breast. Applicable only if patient was disease free after initial surgery. | 0 = None 1 = Chest wall (local) 2 = Ipsilateral axillary nodes or within the axilla if no nodes are mentioned (regional) 3 = Distant (includes distant nodes) 4 = Never disease-free 5 = Non-ipsilateral breast recurrence, but type/site not specified 6 = Recurred, but unknown if in ipsilateral breast or not in ipsilateral |
|||||||||||||||||||||||||||||||||||
| Site of distant recurrence | Site of distant recurrence, if any. Applicable only if patient was disease free after initial surgery. | 01 = Skin 02 = Lymph Nodes 03 = Bone 04 = Lung 05 = Pleura 06 = Liver 07 = CNS 08 = Peritoneum 88 = Other 99 = Unknown NA = Not applicable |
|||||||||||||||||||||||||||||||||||
| Length of follow-up for first recurrence outside of ipsilateral breast | Number of months from date of diagnosis to date of first recurrence outside of the ipsilateral breast. | Integer or blank | |||||||||||||||||||||||||||||||||||
| Indicator of ipsilateral breast recurrence | Ipsilateral breast recurrence. Applicable only if surgery was breast-conserving and patient was disease free following initial surgery. | 0 = No 1 = Yes NA = not applicable |
|||||||||||||||||||||||||||||||||||
| Length of follow-up for ipsilateral breast recurrence | Number of months from date of diagnosis to date of first ipsilateral in-breast recurrence, or to date last verified free of ipsilateral recurrence. | Integer or NA | |||||||||||||||||||||||||||||||||||
| Type of first recurrence-free survival (RFS) event observed | First observed RFS event (ipsilateral invasive breast tumor recurrence, local/regional recurrence, distant recurrence, death due to any cause, or none). Applicable only if patient was disease free after initial surgery. | 1 = Death due to any cause 2 = Distant recurrence 3 = Ipsilateral recurrence 4 = Local/regional recurrence 5 = None 6 = Unknown |
|||||||||||||||||||||||||||||||||||
| Length of follow-up for recurrence-free survival (RFS) | Number of months from date of diagnosis to the date of first ipsilateral invasive breast tumor recurrence, local/regional recurrence, distant recurrence, or death due to any cause. Applicable only if patient was disease free after initial surgery. | Integer or blank | |||||||||||||||||||||||||||||||||||
| ER Score | ASCO CAP Guidelines for ER Scoring. | 0 = Negative (< 1% expressing cells) 1 = Positive (= 1% expressing cells) NA = Not applicable |
|||||||||||||||||||||||||||||||||||
| PR Score | ASCO CAP Guidelines for PR Scoring. | 0 = Negative (< 1% expressing cells) 1 = Positive (= 1% expressing cells) NA = Not applicable |
|||||||||||||||||||||||||||||||||||
| HER2 IHC | ASCO CAP Guidelines for HER2 Scoring. | 0 = No staining 1 = Weak, incomplete membrane staining in any proportion of invasive tumor cells, or weak, complete membrane staining in less than 10% of cells. 2 = Complete membrane staining that is non-uniform or weak but with obvious circumferential distribution in at least 10% of cells, or intense complete membrane staining in 30% or less of tumor cells. 3 = Uniform intense membrane staining of more than 30% of invasive tumor cells. NA = Not applicable |
|||||||||||||||||||||||||||||||||||
| HER2 FISH | ASCO CAP Guidelines for HER2 Scoring. | 0 = Not amplified 1 = Amplified |
|||||||||||||||||||||||||||||||||||
| HER2 Score | Final HER2 result that is a combination of the HER2 IHC and FISH evaluations. HER2 FISH was performed for all 1+ and 2+ HER2 IHC results. | 0 = Negative: IHC Score 0; or IHC Score 1+ or 2+ and HER2 not amplified with FISH 1 = Positive: IHC score 3+; or IHC Score 1+ or 2+ and HER2 amplified with FISH |
|||||||||||||||||||||||||||||||||||
| Comments | Information known about prior or subsequent primary cancers (breast or non-breast) and their recurrences (if any), and any other information pertinent to the interpretation of the case's data. | Text or blank | |||||||||||||||||||||||||||||||||||
Please send comments or concerns about this web site to tissueresources@imsweb.com